Corner Therapeutics files Form D for $48.3 million equity offering tied to AI3 Bio merger
The filing shows the offering followed a merger transaction and lists eight investors who have already put in money, with the full amount sold.
Corner Therapeutics, Inc., doing business as AI3 Bio, Inc., filed a Form D notice with the Securities and Exchange Commission dated November 4, 2026, disclosing an exempt securities offering. The filing marks a new notice, with a date of first sale listed as June 9, 2026.1
The company is incorporated in Delaware and was formed over five years ago, according to the filing.1 AI3 Bio lists its principal place of business at 99 Coolidge Ave, Suite 201, in Watertown, Massachusetts.1 The company identifies its industry as biotechnology.1
The clarification accompanying the filing states that the offering consists solely of an equity financing consummated following the completion of a merger transaction, and that the securities included in this Form D were not issued in the merger.1
On the financial terms, the total offering amount and total amount sold were both listed as $48,339,490, with $0 remaining to be sold.1 The filing reports a total of 8 investors who have already invested in the offering.1 No sales commissions or finders' fees were disclosed, both listed at $0.1 Proceeds allocated to executive officers, directors, or promoters named in the filing were also listed at $0.1
The filing was claimed under Rule 506(b) of the federal exemptions and exclusions section.1 Related persons listed include Steven Altschuler and Nick Seaver, both identified as executive officers and directors, along with Michael Lyman and Jonathan Kagan as executive officers, and Fabian Tenenbaum, Jeanne Cunicelli, and Alan Ezekowitz as directors.1 The form was signed electronically by Steven Altschuler, Chief Executive Officer, on November 4, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.